Effect of nateglinide on the incidence of diabetes and cardiovascular events

Rury R Holman, Steven M Haffner, John J McMurray, M Angelyn Bethel, Björn Holzhauer, Tsushung A Hua, Yuri Belenkov, Mitradev Boolell, John B Buse, Brendan M Buckley, Antonio R Chacra, Fu-Tien Chiang, Bernard Charbonnel, Chun-Chung Chow, Melanie J Davies, Prakash Deedwania, Peter Diem, Daniel Einhorn, Vivian Fonseca, Gregory R FulcherZbigniew Gaciong, Sonia Gaztambide, Thomas Giles, Edward Horton, Hasan Ilkova, Trond Jenssen, Steven E Kahn, Henry Krum, Markku Laakso, Lawrence A Leiter, Naomi S Levitt, Viacheslav Mareev, Felipe Martinez, Chantal Masson, Theodore Mazzone, Eduardo Meaney, Richard Nesto, Changyu Pan, Rudolf Prager, Sotirios A Raptis, Guy E H M Rutten, Herbert Sandstroem, Frank Schaper, Andre Scheen, Ole Schmitz, Isaac Sinay, Vladimir Soska, Steen Stender, Gyula Tamás, Gianni Tognoni, NAVIGATOR Study Group

    466 Citationer (Scopus)

    Abstract

    The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown.
    OriginalsprogEngelsk
    TidsskriftNew England Journal of Medicine
    Vol/bind362
    Udgave nummer16
    Sider (fra-til)1463-76
    Antal sider14
    ISSN0028-4793
    DOI
    StatusUdgivet - 22 apr. 2010

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Effect of nateglinide on the incidence of diabetes and cardiovascular events'. Sammen danner de et unikt fingeraftryk.

    Citationsformater